Peptide Cancer Vaccine Market Size is valued at USD 1.6 Bn in 2024 and is predicted to reach USD 13.9 Bn by the year 2034 at a 24.5% CAGR during the forecast period for 2025-2034.
Peptide cancer vaccines utilize tumour-derived peptides that stimulate T-cell immune responses against cancer, focusing on antigens such as tumour-associated antigens (TAAs) or neoantigens. They are secure, targeted, and economically viable, yet encounter obstacles such as diminished immunogenicity and tumor-induced immunosuppression. Recent trials, such as PGV001, demonstrate potential, particularly with customized neoantigens and checkpoint inhibitors. Numerous significant variables are propelling the market for peptide cancer vaccines. The increasing global incidence of cancer has increased the demand for targeted and advanced treatment options.
Additionally, advancements in personalized medicine and molecular biology have enabled the development of precise and tailored cancer vaccines. Furthermore, as our understanding of the immune system and its role in protecting against cancer has increased, so too has research and funding for immunotherapies, such as peptide vaccines. In addition, the market for peptide cancer vaccines is expanding as a result of supportive government programs, rising healthcare expenditures, and a shift toward preventative healthcare, which creates new opportunities in the fight against cancer.
However, the market for peptide cancer vaccines is limited by competition from alternative therapeutic techniques. Apart from a range of immunotherapies, traditional medicines such as chemotherapy and radiation therapy provide effective alternatives. The proven use and familiarity of existing treatments, along with potential cynicism regarding more novel approaches, may hinder the adoption of peptide cancer vaccines.
The Peptide Cancer Vaccine market is segmented based on type and application. Based on type, the market is segmented into Multivalent Peptide Vaccine, Personalized Peptide Vaccine, Peptide Cocktail Type, Hybrid Peptide Vaccine, and Peptide-Pulsed Dendritic Cancer Vaccine. By application, the market segmentation consists of Breast Cancer, Lung Cancer, Prostate Cancer, and Melanoma.
The Multivalent Peptide Vaccine category is expected to hold a major global market share in 2024. These vaccines are becoming more popular because of a number of advantages, including the fact that they contain all necessary epitopes, are immunogenic, and can be made at a low cost. It is anticipated that multivalent peptide vaccinations will offer strong immune protection, aiding in the fight against the illness. The market expansion in this sector is being propelled by all of these advantages. On the other hand, a notable compound annual growth rate (CAGR) is anticipated for the personalized peptide vaccine during the forecast period. Depending on the host's pre-existing immunity, personalized peptide vaccinations affect T-cells. Based on the host's pre-existing immunity prior to vaccination, the HLA-matched peptides are chosen and given. Clinical therapy options for a variety of advanced tumours have been demonstrated by recent clinical trials on customized peptide vaccines.
In 2024, the Melanoma segment held the largest proportion of the global market revenue, and it is anticipated to continue to do so during the forecast period. Melanoma is a type of cancer that causes skin discolouration. The GP 100 peptide vaccine has been licensed for the treatment of melanoma diseases after being researched and undergoing clinical trials. Following immunization, the T-cells identify and eliminate the cancer cells. In contrast, the market for peptide cancer vaccines is anticipated to see substantial growth in the breast cancer segment during the forecast period. The three single peptide vaccines used to treat breast cancer are AE37, GP2, and E75. The HER2 protein's epitope has nine amino acids, which make up E75 and GP2. Breast cancer is common worldwide, and according to several studies, the risk of developing the disease is predicted to rise by 12% annually.
The North American Peptide Cancer Vaccine market is expected to register the highest market share in revenue in the near future. The growth of the market is being driven by a number of important biotech and pharmaceutical companies in the area. Advanced healthcare systems and research facilities in developed nations like the US and Canada have an impact on the use of peptide cancer vaccines as a treatment.
The government's efforts to educate the public about cancer and available treatments include enacting laws governing treatment reimbursement, which have an impact on market expansion. In addition, Asia Pacific is projected to grow rapidly in the global Peptide Cancer Vaccine market as a result of growing R&D efforts to provide patients with better and more effective care. There are several clinical trials involving peptide cancer vaccines underway, which should have a favourable effect on market revenue. Peptide cancer vaccines are becoming the preferred cancer treatment in developed nations like China, Japan, and Australia, which are well-equipped with cutting-edge medical facilities and research facilities.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.6 Bn |
|
Revenue Forecast In 2034 |
USD 13.9 Bn |
|
Growth Rate CAGR |
CAGR of 24.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
TapImmune, Boston Biomedical, Ultimovacs, OncoTherapy Science, VAXON Biotech, Immatics, Imugene, ISA Pharmaceuticals, Generex Biotechnology, BrightPath Biotherapeutics, Sellas, and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide Cancer Vaccine Market Snapshot
Chapter 4. Global Peptide Cancer Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Peptide Cancer Vaccine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Peptide Cancer Vaccine Market Industry Trends
Chapter 5. Peptide Cancer Vaccine Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Multivalent Peptide Vaccine
5.2.2. Peptide Cocktail Type
5.2.3. Personalized Peptide Vaccine
5.2.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.2.5. Hybrid Peptide Vaccine
Chapter 6. Peptide Cancer Vaccine Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the
following Application:
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Melanoma
6.2.4. Prostate Cancer
Chapter 7. Peptide Cancer Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Peptide Cancer Vaccine Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.2.3. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.3. Europe
7.3.1. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.3.3. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.4.3. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.5. Latin America
7.5.1. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.5.3. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.6.3. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Imugene
8.2.1.1. Business Overview
8.2.1.2. Key Type/Service
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Generex Biotechnology
8.2.3. BrightPath Biotherapeutics
8.2.4. Sellas
8.2.5. TapImmune
8.2.6. OncoTherapy Science
8.2.7. VAXON Biotech
8.2.8. Boston Biomedical
8.2.9. Ultimovacs
8.2.10. Immatics
8.2.11. ISA Pharmaceuticals
8.2.12. Others
Peptide Cancer Vaccine Market By Type-
Peptide Cancer Vaccine Market By Application-
Peptide Cancer Vaccine Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
